Skip to main content
06/10/2016

Dr. Simó Schwartz Jr has been appointed as a member of the advisory board of the EU-NCL

schwartz_jr_884

06/10/2016

VHIR's researcher will collaborate with the European laboratory which performs the characterisation of nanoparticles developed in research centers for therapeutical applications.

Dr. Simó Schwartz Jr, director of the CIBBIM-Nanomedicine of the Vall d'Hebron Institute of Research (VHIR), has been appointed as a member of the advisory board of the http://www.euncl.eu/ Nanomedicine Characterisation Laboratory (EU-NCL). Dr. Schwartz will collaborate with the EU-NCL defining the objectives as well as setting up the strategic plan and director plan.The EU-NCL is an infrastructure, similar to the American Nanotechnology Characterization Laboratory, which offers services of physical and chemical characterisation of the therapeutic nanoconjugates developed by research centers, public laboratories, spin-offs and innovative enterprises.The EU-NCL has 3 members in their external advisory board, among which we can find Dr. Schwartz, and 9 European partners who met for the first time in May in Trondheim, Norway. In the meeting, they reviewed the projects and the work carried out up to date and they set up the collaboration objectives for the financing of new studies.

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.